Degraded DNA may induce discordance of KRAS status between primary colorectal cancer and corresponding liver metastases

International Journal of Clinical Oncology

Volumn 19, Issue 1, 2014, Pages 113-120

  Kaneko, Yuka ^a   Kuramochi, Hidekazu ^a   Nakajima, Go ^a   Inoue, Yuji ^a   Yamamoto, Masakazu ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Bioanalyzer; KRAS; Liver metastases; Mutation

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DNA, NEOPLASM; FEMALE; GENOTYPE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; QUALITY CONTROL; RAS PROTEINS;

EID: 84894519303     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0507-4     Document Type: Article

References (21)

1. Douillard JY, Siena S, Cassidy J, et al. (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28(31):4697-4705
2. Lievre A, Bachet JB, Boige V, et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26(3):374-379
3. Monzon FA, Ogino S, Hammond ME, et al. (2009) The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med 133(10):1600-1606
4. Knijn N, Mekenkamp LJ, Klomp M, et al. (2011) KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 104(6):1020-1026
5. Pao W, Wang TY, Riely GJ, et al. (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2(1):e17
6. Hoshi K, Takakura H, Mitani Y, et al. (2007) Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process. Clin Cancer Res 13(17):4974-4983
7. Mitani Y, Lezhava A, Kawai Y, et al. (2007) Rapid SNP diagnostics using asymmetric isothermal amplification and a new mismatch-suppression technology. Nat Methods 4(3):257-262
8. Araki T, Shimizu K, Nakamura K, et al. (2010) Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon 12 mutations in lung adenocarcinoma: comparison of PNA-clamp SmartAmp2 and PCR-related methods. J Mol Diagn 12(1):118-124
9. Tatsumi K, Mitani Y, Watanabe J, et al. (2008) Rapid screening assay for KRAS mutations by the modified smart amplification process. J Mol Diagn 10(6):520-526
10. Taguchi M, Inoue H, Motani-Saitoh H, et al. (2012) DNA identification of formalin-fixed organs is affected by fixation time and type of fixatives: using the AmpF ℓ STR(R) Identifiler(R) PCR Amplification Kit. Med Sci Law 52(1):12-16
11. Ferrer I, Armstrong J, Capellari S, et al. (2007) Effects of formalin fixation, paraffin embedding, and time of storage on DNA preservation in brain tissue: a BrainNet Europe study. Brain Pathol 17(3):297-303
12. Inoue T, Nabeshima K, Kataoka H, et al. (1996) Feasibility of archival non-buffered formalin-fixed and paraffin-embedded tissues for PCR amplification: an analysis of resected gastric carcinoma. Pathol Int 46(12):997-1004
13. Turashvili G, Yang W, McKinney S, et al. (2012) Nucleic acid quantity and quality from paraffin blocks: defining optimal fixation, processing and DNA/RNA extraction techniques. Exp Mol Pathol 92(1):33-43
14. Van Cutsem E, Kohne CH, Hitre E, et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14):1408-1417
15. Bando H, Tsuchihara K, Yoshino T, et al. (2011) Biased discordance of KRAS mutation detection in archived colorectal cancer specimens between the ARMS-Scorpion method and direct sequencing. Jpn J Clin Oncol 41(2):239-244
16. Dequeker E, Ligtenberg MJ, Vander Borght S, et al. (2011) Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme. Virchows Arch 459(2):155-160
17. Santini D, Loupakis F, Vincenzi B, et al. (2008) High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 13(12):1270-1275
18. Albanese I, Scibetta AG, Migliavacca M, et al. (2004) Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun 325(3):784-791
19. Fukunari H, Iwama T, Sugihara K, et al. (2003) Intratumoral heterogeneity of genetic changes in primary colorectal carcinomas with metastasis. Surg Today 33(6):408-413
20. Baldus SE, Schaefer KL, Engers R, et al. (2010) Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16(3):790-799
21. Watanabe T, Kobunai T, Yamamoto Y, et al. (2011) Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Dis Colon Rectum 54(9):1170-1178